BIOMAT Database Logo BIOMAT Database Logo

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants. 2024

Robert A Smith, and Dana N Raugi, and Robert S Nixon, and Moussa Seydi, and Nicolas A Margot, and Christian Callebaut, and Geoffrey S Gottlieb, and
Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle.

The activity of lenacapavir against human immunodeficiency virus type 1 (HIV-1) has been extensively evaluated in vitro, but comparable data for human immunodeficiency virus type 2 (HIV-2) are scarce. We determined the anti-HIV-2 activity of lenacapavir using single-cycle infections of MAGIC-5A cells and multicycle infections of a T-cell line. Lenacapavir exhibited low-nanomolar activity against HIV-2, but was 11- to 14-fold less potent against HIV-2 in comparison to HIV-1. Mutations in HIV-2 that confer resistance to other antiretrovirals did not confer cross-resistance to lenacapavir. Although lenacapavir-containing regimens might be considered for appropriate patients with HIV-2, more frequent viral load and/or CD4 testing may be needed to assess clinical response.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015498 HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker. HTLV-IV,Human T-Lymphotropic Virus Type IV,Human immunodeficiency virus 2,LAV-2,HIV-II,Human Immunodeficiency Virus Type 2,Human T Lymphotropic Virus Type IV,Immunodeficiency Virus Type 2, Human,SBL-6669
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

Robert A Smith, and Dana N Raugi, and Robert S Nixon, and Moussa Seydi, and Nicolas A Margot, and Christian Callebaut, and Geoffrey S Gottlieb, and
Antiviral activity against human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) of ethnobotanically selected Ethiopian medicinal plants.
February 2001, Phytotherapy research : PTR,
Robert A Smith, and Dana N Raugi, and Robert S Nixon, and Moussa Seydi, and Nicolas A Margot, and Christian Callebaut, and Geoffrey S Gottlieb, and
Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1.
March 1996, Antiviral research,
Robert A Smith, and Dana N Raugi, and Robert S Nixon, and Moussa Seydi, and Nicolas A Margot, and Christian Callebaut, and Geoffrey S Gottlieb, and
Antiviral activity of Hawaiian medicinal plants against human immunodeficiency Virus Type-1 (HIV-1).
January 1996, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Robert A Smith, and Dana N Raugi, and Robert S Nixon, and Moussa Seydi, and Nicolas A Margot, and Christian Callebaut, and Geoffrey S Gottlieb, and
Antiviral activity of fattiviracin FV-8 against human immunodeficiency virus type 1 (HIV-1).
March 2001, Bioscience, biotechnology, and biochemistry,
Robert A Smith, and Dana N Raugi, and Robert S Nixon, and Moussa Seydi, and Nicolas A Margot, and Christian Callebaut, and Geoffrey S Gottlieb, and
Antiviral activity of Rwandan medicinal plants against human immunodeficiency virus type-1 (HIV-1).
January 2002, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Robert A Smith, and Dana N Raugi, and Robert S Nixon, and Moussa Seydi, and Nicolas A Margot, and Christian Callebaut, and Geoffrey S Gottlieb, and
Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
November 2011, Bioorganic & medicinal chemistry letters,
Robert A Smith, and Dana N Raugi, and Robert S Nixon, and Moussa Seydi, and Nicolas A Margot, and Christian Callebaut, and Geoffrey S Gottlieb, and
Antiviral activity of polyoxomolybdoeuropate PM-104 against human immunodeficiency virus type 1.
June 1991, Chemical & pharmaceutical bulletin,
Robert A Smith, and Dana N Raugi, and Robert S Nixon, and Moussa Seydi, and Nicolas A Margot, and Christian Callebaut, and Geoffrey S Gottlieb, and
In vitro sensitivity of clinical isolates and drug-resistant mutants of herpes simplex virus against seven antiviral drugs.
July 1989, Journal of chemotherapy (Florence, Italy),
Robert A Smith, and Dana N Raugi, and Robert S Nixon, and Moussa Seydi, and Nicolas A Margot, and Christian Callebaut, and Geoffrey S Gottlieb, and
P1-substituted symmetry-based human immunodeficiency virus protease inhibitors with potent antiviral activity against drug-resistant viruses.
October 2011, Journal of medicinal chemistry,
Robert A Smith, and Dana N Raugi, and Robert S Nixon, and Moussa Seydi, and Nicolas A Margot, and Christian Callebaut, and Geoffrey S Gottlieb, and
Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2.
March 1996, AIDS research and human retroviruses,
Copied contents to your clipboard!